View ValuationSCHOTT Pharma KGaA 향후 성장Future 기준 점검 1/6SCHOTT Pharma KGaA (는) 각각 연간 9.4% 및 6.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.2% 로 예상됩니다.핵심 정보9.4%이익 성장률9.25%EPS 성장률Life Sciences 이익 성장20.2%매출 성장률6.1%향후 자기자본이익률14.17%애널리스트 커버리지Good마지막 업데이트22 May 2026최근 향후 성장 업데이트Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.모든 업데이트 보기Recent updates공시 • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.공시 • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.공시 • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025공시 • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026공시 • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026공시 • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.공시 • Dec 19SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025, at 10:00 W. Europe Standard Time.공시 • Nov 16+ 3 more updatesSCHOTT Pharma AG & Co. KGaA to Report First Half, 2025 Results on May 15, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2025 results on May 15, 2025공시 • Sep 05SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2024 Results on Dec 12, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2024 results on Dec 12, 2024Reported Earnings • Aug 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: €0.31 (up from €0.20 in 3Q 2023). Revenue: €253.6m (up 15% from 3Q 2023). Net income: €46.3m (up 52% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €36.18, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €46.51 per share.Reported Earnings • Jun 28Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.17. Net income: €25.0m (up €25.0m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €31.78, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €47.63 per share.Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: €0.29 (vs €0.17 in 1Q 2023)First quarter 2024 results: EPS: €0.29 (up from €0.17 in 1Q 2023). Revenue: €232.3m (up 14% from 1Q 2023). Net income: €44.4m (up 74% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Buy Or Sell Opportunity • Feb 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €42.60. The fair value is estimated to be €35.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.공시 • Feb 27+ 1 more updateSCHOTT Pharma AG & Co. KGaA to Report First Half, 2024 Results on Feb 29, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2024 results on Feb 29, 2024Buy Or Sell Opportunity • Feb 01Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.공시 • Sep 29SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million.SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 7,407,407 Price\Range: €27 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 22,715,517 Price\Range: €27 Transaction Features: Regulation S; Rule 144A이익 및 매출 성장 예측DB:1SXP - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/20281,15817810926499/30/20271,08716184239119/30/20261,0131439022693/31/202699114359202N/A12/31/202599515011158N/A9/30/202598614635180N/A6/30/202597714749203N/A3/31/202597414866206N/A12/31/202495613546184N/A9/30/202495715079225N/A6/30/202494915022191N/A3/31/2024916135-3175N/A12/31/202390615836220N/A9/30/20238991526182N/A6/30/202387314372217N/A9/30/202282112529182N/A9/30/202164910134132N/A9/30/20205847719104N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1SXP 의 연간 예상 수익 증가율(9.4%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 1SXP 의 연간 수익(9.4%)이 German 시장(17.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 1SXP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 1SXP 의 수익(연간 6.1%)이 German 시장(연간 6.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 1SXP 의 수익(연간 6.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1SXP의 자본 수익률은 3년 후 14.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 08:04종가2026/05/26 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SCHOTT Pharma AG & Co. KGaA는 23명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gaurav JainBarclaysPallav MittalBarclaysJonathon UnwinBarclays20명의 분석가 더 보기
Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
공시 • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.
공시 • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
공시 • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025
공시 • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026
공시 • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026
공시 • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.
공시 • Dec 19SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025, at 10:00 W. Europe Standard Time.
공시 • Nov 16+ 3 more updatesSCHOTT Pharma AG & Co. KGaA to Report First Half, 2025 Results on May 15, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2025 results on May 15, 2025
공시 • Sep 05SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2024 Results on Dec 12, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2024 results on Dec 12, 2024
Reported Earnings • Aug 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: €0.31 (up from €0.20 in 3Q 2023). Revenue: €253.6m (up 15% from 3Q 2023). Net income: €46.3m (up 52% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €36.18, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €46.51 per share.
Reported Earnings • Jun 28Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.17. Net income: €25.0m (up €25.0m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €31.78, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €47.63 per share.
Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: €0.29 (vs €0.17 in 1Q 2023)First quarter 2024 results: EPS: €0.29 (up from €0.17 in 1Q 2023). Revenue: €232.3m (up 14% from 1Q 2023). Net income: €44.4m (up 74% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Buy Or Sell Opportunity • Feb 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €42.60. The fair value is estimated to be €35.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
공시 • Feb 27+ 1 more updateSCHOTT Pharma AG & Co. KGaA to Report First Half, 2024 Results on Feb 29, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2024 results on Feb 29, 2024
Buy Or Sell Opportunity • Feb 01Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
공시 • Sep 29SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million.SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 7,407,407 Price\Range: €27 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 22,715,517 Price\Range: €27 Transaction Features: Regulation S; Rule 144A